EG BioMed CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
EG BioMed offers a suite of blood-based cancer detection tests based on cfDNA methylation analysis. By evaluating methylation markers in specific genes associated with cancers — such as breast, colon, and pancreatic cancer — their assays provide early det
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90190353
Status
Active
Number of Employees
0
Total Paid-in
Capital
230,300,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EG BioMed focuses on leveraging DNA methylation technology to develop non‑invasive blood tests for early cancer detection, prognosis monitoring, and recurrence surveillance. With a precision‑medicine approach, they aim to make cancer screening more accessible and accurate — empowering clinicians with individualized molecular data for better decision‑making.
The content above was translated by Ai
